V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20120230 | 20134127 | 1.83 | 115.9 | Adjuvant (A) | 2018-07-18 | 2018-07-28 | SCOPE 2 TRIAL | 02 | N | CETUXIMAB + FLUOROURACIL | 100700867 |
| 20120501 | 20134128 | 1.79 | 67.5 | 03 | 2020-10-07 | 2020-10-15 | Irinotecan + Raltitrexed | 02 | null | MPV | 101597204 |
| 20120522 | 20134129 | 1.75 | 62 | Palliative (P) | null | 2019-12-23 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | ETOPOSIDE + IFOSFAMIDE | 101181621 |
| 20120656 | 20134130 | 1.65 | null | Curative (C) | 2018-03-03 | 2018-03-07 | Fluorouracil + Streptozocin | 02 | null | AVAPRITINIB | 100657819 |
| 20120674 | 20134131 | 1.71 | 66.1 | Palliative (P) | 2018-03-04 | 2018-03-26 | Docetaxel + Gemcitabine (prior RT) | 02 | N | NIRAPARIB | 100500928 |
| 20120884 | 20134132 | 1.83 | 81 | null | 2016-01-16 | 2016-02-03 | Bevacizumab + Irinotecan + MdG | 02 | N | VINORELBINE | 101356947 |
| 20120917 | 20134133 | 1.71 | 86.9 | null | 2017-04-30 | 2017-05-10 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | DOCETAXEL + GEMCITABINE | 101524385 |
| 20121101 | 20134136 | 1.83 | 57.75 | Palliative (P) | 2019-02-05 | 2019-02-13 | PHITT F GEMOX / sorafenib | 02 | N | ARISTOTLE TRIAL | 101185358 |
| 20121255 | 20134137 | 1.61 | 91.2 | null | 2022-04-23 | 2022-05-04 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 2 | N | FLUOROURACIL + STREPTOZOCIN | 101389274 |
| 20121298 | 20134138 | 1.87 | 71.4 | null | 2017-10-03 | 2017-10-04 | Carboplatin + Pembrolizumab + Pemetrexed | null | null | ERIBULIN | 101563034 |
| 20121353 | 20134139 | 1.56 | 68.6 | Palliative (P) | 2019-04-22 | 2019-07-11 | Fluorouracil + Folinic + RT Bossett | 02 | N | BEVACIZUMAB + FLUOROURACIL + OXALIPLATIN | 100378787 |
| 20121424 | 20134140 | 1.69 | 82.2 | Palliative (P) | 2019-10-03 | 2019-10-17 | IPILIMUMAB + NIVOLUMAB | 02 | N | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 100191559 |
| 20121595 | 20134141 | 1.89 | 91 | Palliative (P) | null | 2018-09-10 | Hydroxycarbamide | N | null | CARBOPLATIN + TEYSUNO | 100428743 |
| 20121799 | 20134142 | 1.71 | 73.8 | Palliative (P) | 2020-06-28 | 2020-06-28 | Doxorubicin 20mg/m2 7 day | null | null | OLARATUMAB | 101838727 |
| 20121827 | 20134143 | null | null | Palliative (P) | 2020-08-23 | 2020-12-04 | COSMIC TRIAL | 02 | N | CISPLATIN + PEMETREXED | 101766179 |
| 20121990 | 20134144 | 1.66 | 59.6 | null | 2015-05-06 | 2015-07-16 | CAPE + OXALIPLATIN + TRASTUZUMAB | N | null | ISATUXIMAB + POMALIDOMIDE | 101278656 |
| 20122070 | 20134146 | 1.65 | 70 | null | 2018-02-08 | 2018-02-08 | Palbociclib | null | null | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | 101572607 |
| 20122253 | 20134147 | 1.65 | 91.6 | null | 2019-05-04 | 2019-05-14 | ECarboX | 02 | N | CISPLATIN + FLUOROURACIL + RT | 100911718 |
| 20122367 | 20134148 | 1.8 | 74 | Curative (C) | 2019-05-15 | 2019-09-11 | Hepatoblastoma Relapse VI | N | N | VENETOCLAX | 100964969 |
| 20122409 | 20134149 | 1.6 | 82.6 | Curative (C) | null | 2022-05-02 | Hydroxycarbamide | N | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 100193854 |
| 20122467 | 20134150 | 1.97 | 72.1 | Palliative (P) | 2018-01-27 | 2018-02-10 | FCR Oral - Cycle 2 onwards | 01 | N | PEMETREXED | 101785734 |
| 20122584 | 20134151 | 1.56 | 0 | Palliative (P) | 2017-10-03 | 2017-10-04 | Bevacizumab + FLUOROURACIL + IRINOTECAN | 02 | N | NIRAPARIB | 100795329 |
| 20122862 | 20134153 | 1.61 | 69.3 | null | 2019-07-16 | 2019-07-19 | Cisplatin + Pemetrexed | N | N | BEVACIZUMAB + CAPECITABINE + IRINOTECAN | 101168979 |
| 20122938 | 20134154 | 1.54 | 93.4 | null | null | 2021-07-12 | ECarboF | null | N | CAP + RT | 100259335 |
| 20123016 | 20134155 | 1.65 | 80 | Palliative (P) | 2019-08-12 | 2019-12-31 | AXITINIB | 02 | null | GEMCITABINE + PACLITAXEL | 101017673 |
| 20123124 | 20134156 | 1.77 | 56.6 | null | 2021-04-23 | 2021-05-03 | ETOPOSIDE | 01 | null | AVAPRITINIB | 100010387 |
| 20123134 | 20134157 | 1.46 | 65.4 | Palliative (P) | 2017-12-23 | 2018-01-16 | Methotrexate intrathecal | 02 | N | CARFILZOMIB | 101070848 |
| 20123140 | 20134158 | 1.6 | 60 | Adjuvant (A) | 2018-12-02 | 2018-12-06 | null | N | null | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 101760433 |
| 20123315 | 20134159 | 1.8 | 70.7 | null | 2021-04-20 | 2021-05-05 | Docetaxel + Trastuzumab (SC) | 02 | N | PHITT D SIOPEL-4 (A1, A2, A3) | 101147115 |
| 20123388 | 20134160 | 1.69 | 73.2 | Adjuvant (A) | 2017-07-22 | 2017-07-30 | Hepatoblastoma SR PLADO | 02 | null | ERIBULIN | 100029959 |
| 20123395 | 20134161 | 1.7 | 65 | Curative (C) | 2018-01-14 | 2018-01-23 | DOXORUBICIN | 2 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100707225 |
| 20123432 | 20134162 | 1.69 | 48 | Palliative (P) | 2019-05-18 | 2019-05-19 | Carboplatin + Pemetrexed | 02 | N | OSIMERTINIB | 100581735 |
| 20123468 | 20134163 | 1.83 | 106 | Palliative (P) | 2019-09-18 | 2019-09-21 | ECarboX | 02 | N | LOMUSTINE + PROCARBAZINE + VINCRISTINE | 100203840 |
| 20123528 | 20134165 | 1.77 | 95.4 | Palliative (P) | null | 2018-07-23 | DARATUMUMAB | 01 | N | ATEZOLIZUMAB | 101636343 |
| 20123554 | 20134166 | 1.55 | 61.7 | null | null | 2021-08-05 | Fluorouracil + Folinic + RT Bossett | Y | null | IRINOTECAN + MDG + PANITUMUMAB | 101836806 |
| 20123720 | 20134167 | 1.81 | 73.2 | Palliative (P) | 2019-10-10 | 2019-10-16 | Pemetrexed | N | N | ECARBOX | 100302272 |
| 20123749 | 20134168 | 1.82 | 65.6 | 03 | null | 2021-07-02 | DARATUMUMAB | 02 | N | RITUXIMAB | 100014955 |
| 20123916 | 20134169 | 1.53 | 57.5 | Curative (C) | 2016-05-24 | 2016-06-07 | ECF | N | N | CT7001 TRIAL | 100148757 |
| 20123917 | 20134170 | 1.6 | 67 | 03 | 2018-07-20 | 2018-12-20 | CHOP R - 21 days | 01 | N | CAPECITABINE + CISPLATIN + STREPTOZOCIN | 100494997 |
| 20124005 | 20134172 | null | 78 | Palliative (P) | 2018-02-09 | 2018-03-18 | TEMOZOLOMIDE | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101570061 |
| 20124035 | 20134173 | 1.61 | 63.2 | Palliative (P) | 2019-03-06 | 2019-04-12 | COSMIC TRIAL | N | null | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100810211 |
| 20124045 | 20134174 | null | 77.3 | Curative (C) | 2017-08-18 | 2018-10-30 | Topotecan (intravenous) | N | N | CHLORAMBUCIL | 100831046 |
| 20124067 | 20134175 | 1.82 | 67 | Curative (C) | 2014-11-03 | 2018-05-02 | Doxorubicin + Olaratumab | 2 | N | HEPATOBLASTOMA HR CARBO/DOX | 100017932 |
| 20124087 | 20134176 | 1.7 | 52 | Palliative (P) | 2018-05-30 | 2018-06-01 | CAPECITABINE + OXALIPLATIN + Trastuzumab | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100508317 |
| 20124470 | 20134178 | 1.68 | 68.9 | Curative (C) | 2017-05-28 | 2017-06-11 | DABRAFENIB + TRAMETINIB | 02 | Y | NAB-PACLITAXEL | 100368605 |
| 20124526 | 20134180 | 1.8 | 95 | Curative (C) | 2018-10-22 | 2019-01-13 | Cyclophosphamide High Dose | N | N | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100138254 |
| 20124670 | 20134181 | 1.58 | 54 | Palliative (P) | 2019-03-21 | 2019-03-21 | Pemetrexed | 02 | N | OXALIPLATIN + MDG + PANITUMUMAB | 100804200 |
| 20124931 | 20134182 | 1.65 | 113 | Palliative (P) | 2018-06-28 | 2019-04-05 | Cisplatin +FU +Trastuzumab - Load | null | N | BCG | 101162702 |
| 20125007 | 20134183 | 1.6 | 50.1 | Neo-adjuvant (N) | 2018-04-07 | 2018-04-08 | Paclitaxel albumin (Abraxane) 7 day | Y | Y | CISPLATIN + CYTARABINE + ETOPOSIDE + RITUXIMAB | 101054220 |
| 20125058 | 20134184 | 1.8 | 75 | null | 2016-04-29 | 2016-11-29 | Bortezomib + Panobinostat | 99 | N | CISPLATIN + RALTITREXED | 101523786 |